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Abstract
This review is intended to provide physicians with an overview of the benefits and risks associated
with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of their patients
with mild-to-moderate osteoarthritis (OA). New information on the inflammatory component of
OA and the cardiovascular (CV) risk associated with cyclooxygenase (COX)-2-specific inhibitors
has prompted efforts to revise the current recommendations for the use of NSAIDs in the
treatment of patients with OA. Clinical studies have shown that naproxen and ibuprofen are
significantly more effective at reducing OA pain than is acetaminophen, the traditional first-line
therapy, which has no apparent anti-inflammatory activity in the joints. The theoretical advantage
of COX-2-specific inhibitors in reducing gastrointestinal (GI) toxicity has been demonstrated by
clinical studies. GI complications can be reduced by using lower NSAID doses for the shortest
duration or with a concomitant proton-pump inhibitor. All prescription NSAIDs carry a black box
warning regarding CV risks; these risks vary among the NSAIDs. While ibuprofen and diclofenac
are associated with an increased CV risk, naproxen was associated with a neutral CV risk relative
to placebo. Ibuprofen, but not naproxen, attenuates the antiplatelet effects of aspirin. An
understanding of the risks and benefits is important when choosing an NSAID. An exhaustive
search of the medical literature since 1990 was conducted using the words "ibuprofen,"
"naproxen," "COX-2-specific NSAIDs," "nonspecific NSAIDs," "low-dose aspirin," and
"nonprescription dosage." Databases searched included MEDLINE, EMBASE, and SCISEARCH. This
article provides primary care physicians with the information needed to assist them in making more
informed decisions in managing patients experiencing mild-to-moderate OA pain.
Introduction
Patients with musculoskeletal diseases such as osteoar-
thritis (OA) are typically managed with a combination of
nonpharmacologic modalities and pharmacologic agents
that are chosen to pose a minimal risk of side effects. The
main goals of this approach are to control pain and
improve function and health-related quality of life. Non-
steroidal anti-inflammatory drugs (NSAIDs) are the most
frequently prescribed drugs for managing musculoskeletal
pain. The clinical usefulness of these agents in relieving
mild-to-moderate pain needs to be balanced with a con-
sideration of adverse effects, including gastrointestinal
(GI) bleeding and perforation[1]. Therefore, clinicians
treating patients with OA need to be aware of the safety
and efficacy profiles of currently available prescription
and over-the-counter (OTC) NSAIDs. A systemic search of
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ate OA was conducted between January 1990 and Febru-
ary 2008. Key search terms included: "ibuprofen,"
"naproxen," "NSAIDs," "COX-2-specific NSAIDs," "non-
specific NSAIDs," "low-dose aspirin," and "nonprescrip-
tion dosage." Randomized clinical trials, epidemiologic
or observational studies, meta-analyses and systemic
reviews, and cardiovascular and GI risk were also
reviewed. Databases searched included MEDLINE,
EMBASE, and SCISEARCH. This review of the NSAID class
will help primary care physicians choose the appropriate
treatment for their patients with OA and musculoskeletal
pain.
NSAIDs: overview and mechanism of action
The NSAIDs are a heterogeneous group of compounds
that exhibit anti-inflammatory, analgesic, and antipyretic
properties. NSAIDs that have been approved by the US
Food and Drug Administration (FDA) for OTC analgesic
use can be separated into three groups: salicylates, repre-
sented by aspirin; propionic acid derivatives, including
ibuprofen and naproxen sodium; and the para-ami-
nophenols, represented by acetaminophen (Table 1).
While ibuprofen and naproxen are both considered tradi-
tional NSAIDs, acetaminophen is not. Although acetami-
nophen has weak cyclooxygenase (COX) inhibition
activity, it appears to have little anti-inflammatory activ-
ity, especially in the high-peroxide environment of OA-
affected joints[2].
The inhibition of prostaglandin production by NSAIDs
was first demonstrated in 1971; this work ultimately led
to the researchers receiving a Nobel Prize in Medicine[3].
This activity, distinct from that of other analgesics, was
speculated to be the action that mediated the gastric side
effects commonly observed with the NSAIDs[3]. The
mechanism of action of the NSAIDs is based on the inhi-
bition of the COX isoenzymes, COX-1 and COX-2. Non-
selective NSAIDs inhibit both COX-1 and COX-2, whereas
COX-2-specific inhibitors have a minimal effect on COX-
1. COX-1 is present constitutively in most normal cells
and tissues; it stimulates prostaglandin synthesis, regu-
lates platelet aggregation, and modulates vascular home-
ostasis, the mucosal integrity of the GI tract, and the
functioning of the renal system. COX-2, in contrast, is a
key mediator of inflammation; it is induced in response to
inflammatory stimuli, initiating pain and the inflamma-
tory response[4].
The analgesic effects of NSAIDs have been attributed to
the inhibition of COX-2, while the GI side effects are
thought to be derived from the inhibition of COX-1.
COX-2-specific inhibition was anticipated to preserve
effective anti-inflammatory activity while causing little or
no associated GI toxicity[5,6]. However, the inhibition of
COX-2 results in reduced production of prostaglandin I2
by vascular endothelium, which may contribute to an
increased risk for thrombosis[7]. In addition, antiplatelet
effects of NSAIDs are thought to be derived primarily from
COX-1 inhibition; thus, the diminished antiplatelet effect
is due to the imbalance between prostacyclin and throm-
boxane production[5,7].
NSAID benefits in pain management
In acute settings, the analgesic effects of non-aspirin
NSAIDs are comparable to those of starting doses of opi-
oids[5,8]. However, unlike opioids, NSAIDs have a ceiling
dose above which no additional pain relief occurs,
although higher doses do mediate anti-inflammatory
effects[8]. Clinical studies in patients with arthritis have
shown that non-aspirin NSAIDs are comparable to aspirin
in reducing pain, joint swelling, and duration of morning
stiffness, as well as in improving strength and mobility[9].
In randomized, double-blind, controlled trials using
acetaminophen as the comparator, diclofenac, a nonselec-
tive NSAID[10], and celecoxib, a COX-2-specific
Table 1: Commercially available nonprescription NSAIDs
Generic drug name Principal brand name in United States OTC dosage Maximum OTC daily dosagea
Salicylates




Ibuprofen Advil®, Midol®, Motrin®, Nuprin® 200–400 mg
q4-6h
1200 mgb




Acetaminophen Tylenol® (plus many combination products) 650–1000 mg
q4-6h
4000 mgb
NSAIDs = nonsteroidal anti-inflammatory drugs; OTC = over-the-counter.
aAdministered over a 10-day period.
bPersons aged ≥60 years should check with a physician prior to taking any medication.Page 2 of 7
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ness.
A growing body of evidence has identified inflammation
as an important component of the pathogenesis of OA
and OA-related pain[12,13]. Inflammatory cytokines and
proteases contribute to a varying extent in the process of
joint destruction[12] and exacerbation of nocicep-
tion[14]. Individual differences in both the degree of
inflammation and susceptibility to nociception sensitiza-
tion may explain, at least in part, why some patients with
limited disease radiographically have severe pain, while
other patients with more severe deterioration of the joint
have minimal pain[15]. For this reason, the use of analge-
sics without anti-inflammatory properties in the joints,
such as acetaminophen, would only provide pain relief
without clinically beneficial anti-inflammatory activ-
ity[16,17].
Among the nonselective NSAIDs, both ibuprofen and
naproxen are available in OTC and prescription dosing
options. The safety and efficacy of OTC dosing of ibupro-
fen and naproxen have been assessed in large clinical tri-
als[18]. OTC doses of both ibuprofen and naproxen
provided significantly improved pain control over pla-
cebo. Similarly, ibuprofen[19] and naproxen[20] have
been shown to be significantly more effective than aceta-
minophen for the treatment of pain associated with OA.
A comparison of ibuprofen with acetaminophen found
that pain relief was superior with ibuprofen, both after
single dosing (ibuprofen 400 mg, acetaminophen 1000
mg) and after 14 days of treatment (ibuprofen 400 mg,
acetaminophen 1000 mg)[19]. Similarly, pain relief with
naproxen versus placebo at dosages of 660 mg/day (440
mg/day in patients ≥65 years old) was greater than that of
acetaminophen versus placebo at dosages of 4000 mg/
day[20].
Patients without contraindicating conditions (pain per-
sisting for >2 weeks, pain with nausea or severe vomiting,
weakness in any limb, pain in a red, hot, or swollen joint,
suspected fracture, pelvic or abdominal pain, suspected
pregnancy, and increased intensity of pain or any change
in the character of pain), can self-treat using OTC
NSAIDs[21] over a period of 10 days or less. Use of these
agents for more than 10 days, even at recommended non-
prescription doses, requires the supervision of a physi-
cian, as long-term self-treatment could mask a more




NSAID use has long been associated with GI side effects,
including dyspepsia, heartburn, and nausea. Serious clin-
ical GI complications occur in up to 4% of patients taking
nonselective NSAIDs at prescription dosages[23]. Endo-
scopic studies suggest that up to 30% of regular nonselec-
tive NSAID users may develop gastric or duodenal
ulcers[24]. The risk for developing GI complications is
greater in patients who are treated with high doses of
NSAIDs or treated for extended periods of time, and also
in patients who take multiple NSAIDs concomitantly.
Patients with prior ulcer or bleeding complications,
patients ≥60 years of age, and patients taking concomitant
aspirin, corticosteroids, or anticoagulants are also at
increased risk[25]. NSAID-related GI complications and
mortality have declined since 1992 in response to the use
of lower NSAID doses and the use of combination therapy
with proton-pump inhibitors[26].
The COX-2-specific inhibitors were expected to deliver
equivalent pain relief to that of the nonselective NSAIDs
but without the accompanying risk of GI complications.
Although they did not eliminate this risk altogether, most
clinical trials involving COX-2-specific inhibitors did
show a lower incidence of upper GI adverse effects than
the nonselective inhibitors[24,27]. However, the
Celecoxib Long-term Arthritis Safety Study (CLASS),
which combined the results from two prospective trials
comparing celecoxib with diclofenac and ibuprofen,
showed no significant difference between the groups in
the rate of upper GI ulcer complications (0.7% for
patients receiving celecoxib versus 1.5% for patients
receiving either of the nonselective NSAIDs)[27-29]. The
primary end point measured was the presence of compli-
cated ulcers (i.e. ulcers requiring hospitalization and
resulting in significant morbidity, mortality, or both).
When patients receiving concomitant low-dose aspirin
(about 20% of the total) were excluded from the analysis,
celecoxib was associated with a significantly lower inci-
dence of symptomatic ulcers and/or ulcer complications
compared with the nonselective NSAIDs[29,30].
Cardiovascular effects
A number of large clinical trials have revealed that the
COX-2-specific inhibitors are associated with an increased
risk of cardiovascular (CV) toxicity[24,31,32]. The Vioxx
Gastrointestinal Outcomes Research (VIGOR) study dem-
onstrated a 5-fold increase in the incidence of myocardial
infarction in rheumatoid arthritis patients treated with the
COX-2-specific inhibitor rofecoxib, as compared with
naproxen[24]. In a randomized, placebo-controlled clini-
cal trial evaluating the COX-2 inhibitor rofecoxib for the
chemoprevention of colorectal neoplasia (The Adenoma-
tous Polyp Prevention On Vioxx [APPROVe] trial), the
patients randomized to rofecoxib had a 2-fold increase in
vascular events (46 thrombotic events) compared with
patients who received placebo (26 events)[31]. This trial
involved 2586 patients who had a history of colorectalPage 3 of 7
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the manufacturer to voluntarily withdraw the product
from the market in 2004[33]. The fact that an increased
risk of serious CV events was also seen in clinical trials
with the COX-2-specific inhibitors parecoxib and val-
decoxib suggested a possible class effect[34].
Currently, the only COX-2-specific NSAID available in the
United States is celecoxib, and the evidence for increased
CV risk with this drug is conflicting. The Adenoma Preven-
tion with Celecoxib (APC) study compared 2 dosages of
celecoxib (200 mg twice daily and 400 mg twice daily)
with placebo in 2035 patients[32]. Results showed a 2- to
3-fold increase in relative risk of serious CV events with
celecoxib versus placebo after a mean duration of 33
months. The Prevention of Colorectal Sporadic Adenom-
atous Polyps (PreSAP) trial, in contrast, showed no
increased CV risk with celecoxib compared with placebo
in 1561 patients[35]. The difference in celecoxib dosing
between the two trials – 400 mg once daily in PreSAP,
compared with 200 mg or 400 mg twice daily in APC –
suggests that the occurrence of CV events may be related
to both the dose and the pharmacokinetics of
celecoxib[35].
Because of the CV risks of COX-2-specific NSAIDs, and
despite the lack of a definitive conclusion about the
potential CV risk of nonselective NSAIDs, the FDA
requires a "black box" warning on all prescription
NSAIDs, stating that "NSAIDs may cause an increased risk
of serious CV thrombotic events, myocardial infarction,
and stroke."[23] This issue, and related issues on the com-
parative efficacy and GI safety of the NSAIDs, was suffi-
ciently important to prompt the Agency for Healthcare
Research and Quality to commission a thorough assess-
ment of all the available evidence on NSAIDs to best
answer these questions[30]. This systematic review of the
evidence showed that the CV safety of naproxen was mod-
erately superior to that of any COX-2-specific NSAID.
Data showed 3.3 additional myocardial infarctions for
every 1000 patients treated with any COX-2 inhibitor
instead of naproxen for 1 year. In contrast, the CV safety
of nonselective NSAIDs other than naproxen (data prima-
rily on diclofenac and ibuprofen) was found to be compa-
rable to that of the COX-2-specific NSAIDs[30]. In
addition, observational studies and indirect analyses of
randomized trials indicated that the CV risk of naproxen
was neutral relative to placebo, whereas comparisons of
ibuprofen and diclofenac with placebo showed an
increased risk of CV events[30,36].
Effects on concomitant use of low-dose aspirin
Aspirin is widely used by patients with OA as prophylaxis
against CV disease. Drug interactions between aspirin and
analgesics commonly used by these patients are therefore
important to recognize. In particular, ibuprofen appears
to antagonize the platelet-inhibiting activity of aspirin,
limiting its cardioprotective effects[37]. This antagonism
may help to explain why there were a higher number of
CV events in patients taking ibuprofen plus low-dose aspi-
rin than in patients taking lumiracoxib plus aspirin in a
post-hoc analysis of CV safety data from the Therapeutic
Arthritis Research and Gastrointestinal Event Trial (TAR-
GET)[38]. Ibuprofen's interference with the cardioprotec-
tive effect of low-dose aspirin is thought to be mediated
by the competitive inhibition of COX-1[39]. It is not
known if this is the case for other nonselective NSAIDs.
The FDA has approved enhanced warning labels for all
OTC NSAIDs. These new labels will provide consumers
with more information about potential CV, GI, and aller-
gic risks[40].
In contrast, when naproxen is coadministered with low-
dose aspirin, its antiplatelet effects (as measured by serum
thromboxane inhibition) are equivalent to those of low-
dose aspirin alone. During the dosing period, this is true
for both prescription doses[41] and nonprescription
doses[42] of naproxen. When measured independently,
the antiplatelet effects of low-dose aspirin, OTC-dose
naproxen (220 mg bid and tid), and prescription-dose
naproxen (550 mg bid) are equivalent[43].
COX-2-specific inhibitors seem to lose their favorable GI
safety profile when they are given concomitantly with
low-dose aspirin[30,44]. Data from the CLASS study
showed that celecoxib was associated with a significantly
lower rate of serious GI adverse events than were nonse-
lective NSAIDs among the 80% of patients not receiving
low-dose aspirin, but not among the 20% of patients
receiving low-dose aspirin[29]. Similar findings were
reported in TARGET, which compared the COX-2-specific
NSAID lumiracoxib with naproxen and ibuprofen in
patients with OA[27].
Choosing an NSAID for an OA patient
Various clinical guidelines have been proposed for the
management of patients with OA[45-47], the most recent
of which was published in February 2008[44]. The 1995
American College of Rheumatology (ACR) guidelines for
the medical management of OA of the hip recommended
acetaminophen as first-line therapy, permitting the use of
a nonselective NSAID if pain control with acetaminophen
was inadequate. This recommendation was based on the
association of nonselective NSAIDs with GI toxicity[46].
The updated 2000 ACR guidelines recommended COX-2-
specific inhibitors as second-line treatment choices after
acetaminophen[45]. This recommendation was based on
the improved GI safety of these agents over that of nonse-
lective NSAIDs, especially in high-risk populations. How-
ever, rofecoxib, one of the COX-2 specific inhibitors, wasPage 4 of 7
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increased risk of serious CV events[33]. The ACR guide-
lines also recommended use of a nonselective NSAID
instead of acetaminophen, or with acetaminophen as
add-on therapy, if pain control was insufficient[45]. Sim-
ilarly, the American Pain Society guidelines from 2002
also recommended acetaminophen as a first-line
agent[47].
The Osteoarthritis Research Society International (OARSI)
has recently published (2008) its recommendations for
the management of OA of the knee and hip[44]. These
recommendations are based on a comprehensive review
of the published literature and the existing guidelines for
the treatment of OA. Consistent with existing guidelines,
OARSI indicates that acetaminophen (up to 4 g/day) can
be used as initial therapy in patients with mild-to-moder-
ate pain from OA of the knee and hip. If response to aceta-
minophen is inadequate, or if pain or inflammation (or
both) is severe, OARSI recommends that alternative phar-
macotherapy be considered. In patients with symptomatic
OA of the knee or hip, OARSI recommends use of the low-
est effective dose of NSAIDs, for the shortest possible
period of time. The important point to note in these 2008
guidelines is that acetaminophen is used for the treatment
of mild-to-moderate pain, while NSAIDs are recom-
mended in symptomatic patients who have both pain and
inflammation. These updated recommendations are
based on previously cited data[16,17] showing that anal-
gesics such as acetaminophen relieve pain but do not pro-
vide anti-inflammatory activity within the joint. Patients
at increased GI risk should receive either a proton-pump
inhibitor or misoprostol concomitantly with their NSAID
for gastroprotection.
In light of the increased risk for GI and CV events in
patients with OA, a simple stratification grid was recently
proposed to guide clinicians in selecting the most appro-
priate NSAID for OA patients by evaluating their CV and
GI risk factors (Table 2)[48]. The stratification grid directs
clinicians to choose monotherapy with a nonselective
NSAID for patients who do not have CV risk factors and
are at low risk for GI events. For patients without CV risk
but with elevated risk for GI complications and who are
not taking aspirin, the recommended treatment is mono-
therapy with a COX-2-specific inhibitor or combination
therapy with a nonselective NSAID plus a proton-pump
inhibitor to mitigate GI risk[49,50]. Patients who are at
increased CV risk and who require aspirin prophylaxis
should be treated with a nonselective NSAID that has
been proven to not compromise the antiplatelet effects of
aspirin. Although aspirin is approved by the FDA for pri-
mary and secondary prevention in a number of CV patient
populations[51], concomitant administration of aspirin
with ibuprofen has been shown to decrease the cardiopro-
tective effects of aspirin[37]. This effect has not been seen
in patients treated concomitantly with aspirin and
naproxen[38]. If these patients require gastroprotection, a
proton-pump inhibitor is again suggested; COX-2-specific
inhibitors should be avoided in these patients[25,48].
Conclusion
The management of patients with mild-to-moderate OA
involves careful consideration of the benefits and risks of
currently available NSAIDs. Medication should be
selected on the basis of pain intensity, inflammation, and
GI and CV risk factors. Recent data seems to indicate that
acetaminophen may not be as effective as the NSAIDs in
symptomatic patients with pain and inflammation.
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for patients with prior GI bleeding
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NSAID combination warrants gastroprotection
• Naproxen if CV risk outweighs GI risk
• COX-2-specific inhibitor + proton-pump inhibitor 
for patients with previous GI bleeding
COX-2 = cyclooxygenase-2; CV = cardiovascular; GI = gastrointestinal; NSAID = nonsteroidal anti-inflammatory drug.
aMisoprostol at full dosage (200 μg qid) may be substituted for a proton-pump inhibitor.
bNonselective or selective (low-dose) inhibitor without established aspirin interaction if naproxen is ineffective.
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